We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Makers of implantable radio-frequency transponder systems can soon begin marketing their devices without being subject to 510(k) premarket notification requirements, according to an FDA guidance document.